The DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Glioma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273 · cited 10×
“Four molecular subtypes of diffuse midline gliomas, H3 K27 altered have been identified, which share loss of nuclear expression of the histone H3 protein trimethylated at lysine 27 (H3K27me3) 3 .”
InfluentialSelf-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“Transcriptome-based studies have stratified glioblastoma into classic, mesenchymal, proneural and neural tumours 55 , with proneural, classic and mesenchymal tumours largely corresponding to the RTK1, RTK2/classic and mesenchymal subtypes, respectively, defined by methylation analysis 54 .”
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“3 codon 34 missense variant (H3.”
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · cited 1×
“Primer mitogen-activated protein kinase (MAPK) and protein kinase B–AKT (PKB–AKT) signalling cascades, or result in TERT activation or ATRX inactivation 51 .”
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“These advances include functional imaging, neuronavigation, intra-operative mapping, awake craniotomy, intra-operative MRI and use of porphyrin dyes such as 5-aminolevulinic acid to define tumour for resection 140,141 .”
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“…of α-KG-dependent dioxygenases, including histone demethyl-ases and the ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases 37 , leading to increased histone methylation and DNA hyper-methylation in IDH-mutant glioma cells, referred to as the glioma CpG island methylator…”
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Self-citationA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“Further challenges in glioma diagnostics relate to improving time to final diagnosis, as molecular testing increases time to final diagnosis, but it should not cause delay of postsurgical treatments.”
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048 · cited 16×
“Primer oligodendroglioma, IDH mutant and 1p/19q codeleted were alive at 20 years after diagnosis and 30% had no recurrence 157 .”
InfluentialSelf-citationSturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Self-citationElectrical and synaptic integration of glioma into neural circuits
Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., Tam, L. T., Espenel, C., Ponnuswami, A., Ni, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1563-y · Cited by 1,366 · cited 2×
“These neuron-to-glioma synapses promote glioma proliferation, growth and invasion through incompletely understood mechanisms involving membrane depolarization, calcium signalling and other voltage-sensitive intracellular cascades 77,79,80 .”
Self-citationCurrent state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Self-citationOstrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad149 · Cited by 1,294
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Pajtler, K. W., Witt, H., Sill, M., Jones, D. T. W., Hovestadt, V., Kratochwil, F., Wani, K., Tatevossian, R., Punchihewa, C., Johann, P., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.002 · Cited by 1,225
Mackay, A., Burford, A., Carvalho, D., Izquierdo, E., Fazal-Salom, J., Taylor, K. R., Bjerke, L., Clarke, M., Vinci, M., Nandhabalan, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.017 · Cited by 1,212
Self-citationGlutamatergic synaptic input to glioma cells drives brain tumour progression
Venkataramani, V., Tanev, D. I., Strahle, C., Studier-Fischer, A., Fankhauser, L., Kessler, T., Körber, C., Kardorff, M., Ratliff, M., Xie, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1564-x · Cited by 1,197 · cited 1×
“This process occurs through activity-regulated paracrine growth factors such as neuroligin 3, BDNF, IGF1 and others 75,76 , and through electrophysiologically functional neuron-to-glioma synapses mediated by calcium-permeable AMPA receptors 77,78 .”
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationCairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Self-citationWeller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Self-citationWeller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Self-citationthe St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064 · cited 1×
“Wait and see or radiotherapy followed by PCV Radiotherapy followed by temozolomide”
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J.-P., Iacobuzio-Donahue, C. A., Brennan, C., Tabar, V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,037
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Self-citationNeuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion
Venkatesh, H. S., Johung, T. B., Caretti, V., Noll, A., Tang, Y., Nagaraja, S., Gibson, E. M., Mount, C. W., Polepalli, J., Mitra, S. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.012 · Cited by 963
Self-citationPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationGD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Self-citationRecurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304194 · Cited by 814
Self-citationExploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationNorthrup, H., Aronow, M. E., Bebin, E. M., Bissler, J., Darling, T. N., de Vries, P. J., Frost, M. D., Fuchs, Z., Gosnell, E. S., Gupta, N., et al. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.07.011 · Cited by 736
Shaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.126 · Cited by 730
Genetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687 · cited 1×
“Paediatric-type diffuse high-grade gliomas with DNA MMR deficiency causing high tumour mutational burden may respond to checkpoint inhibitor therapy 240 .”
Self-citationFriebel, E., Kapolou, K., Unger, S., Núñez, N. G., Utz, S., Rushing, E. J., Regli, L., Weller, M., Greter, M., Tugues, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.055 · Cited by 685
Self-citationC11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
An, Z., Aksoy, O., Zheng, T., Fan, Q.-W., & Weiss, W. A. (2018) · Oncogene · doi:10.1038/s41388-017-0045-7 · Cited by 668
Castel, D., Philippe, C., Calmon, R., Le Dret, L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 664
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Packer, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., et al. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.5.0747 · Cited by 636
Glioblastoma hijacks neuronal mechanisms for brain invasion
Venkataramani, V., Yang, Y., Schubert, M. C., Reyhan, E., Tetzlaff, S. K., Wißmann, N., Botz, M., Soyka, S. J., Beretta, C. A., Pramatarov, R. L., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.054 · Cited by 632
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Self-citationLongitudinal molecular trajectories of diffuse glioma in adults
Barthel, F. P., Johnson, K. C., Varn, F. S., Moskalik, A. D., Tanner, G., Kocakavuk, E., Anderson, K. J., Abiola, O., Aldape, K., Alfaro, K. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1775-1 · Cited by 561
Self-citationSulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 555
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Bunse, L., Pusch, S., Bunse, T., Sahm, F., Sanghvi, K., Friedrich, M., Alansary, D., Sonner, J. K., Green, E., Deumelandt, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0095-6 · Cited by 539
Self-citationLim, M., Weller, M., Idbaih, A., Steinbach, J., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J., Taylor, J. W., Honnorat, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac116 · Cited by 533
Self-citationSeizure characteristics and control following resection in 332 patients with low-grade gliomas
Chang, E. F., Potts, M. B., Keles, G. E., Lamborn, K. R., Chang, S. M., Barbaro, N. M., & Berger, M. S. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/2/0227 · Cited by 526
Self-citationIntratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac099 · Cited by 516
Self-citationFangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P. J., Rietberg, S. P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0006-x · Cited by 499
Self-citationIntegrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457
Self-citationWang, Y., Springer, S., Zhang, M., McMahon, K. W., Kinde, I., Dobbyn, L., Ptak, J., Brem, H., Chaichana, K., Gallia, G. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511694112 · Cited by 454
Self-citationLiau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5370 · Cited by 451
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Monoclonal antibody specific for IDH1 R132H mutation
Capper, D., Zentgraf, H., Balss, J., Hartmann, C., & von Deimling, A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0595-z · Cited by 436
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Qaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Epidemiology of brain metastases and leptomeningeal disease
Lamba, N., Wen, P. Y., & Aizer, A. A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab101 · Cited by 406
Self-citationTranscriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
Self-citationvan den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Self-citationKarschnia, P., Young, J. S., Dono, A., Häni, L., Sciortino, T., Bruno, F., Juenger, S. T., Teske, N., Morshed, R. A., Haddad, A. F., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac193 · Cited by 384
Self-citationEpileptic seizures in diffuse low-grade gliomas in adults
Pallud, J., Audureau, E., Blonski, M., Sanai, N., Bauchet, L., Fontaine, D., Mandonnet, E., Dezamis, E., Psimaras, D., Guyotat, J., et al. (2014) · Brain · doi:10.1093/brain/awt345 · Cited by 380
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 369
Self-citationMcBrayer, S. K., Mayers, J. R., DiNatale, G. J., Shi, D. D., Khanal, J., Chakraborty, A. A., Sarosiek, K. A., Briggs, K. J., Robbins, A. K., Sewastianik, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.038 · Cited by 368
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Corticosteroids compromise survival in glioblastoma
Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S., Dai, C., Ozawa, T., Chang, M., Chan, T. A., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 363
Self-citationHarutyunyan, A. S., Krug, B., Chen, H., Papillon-Cavanagh, S., Zeinieh, M., De Jay, N., Deshmukh, S., Chen, C. C. L., Belle, J., Mikael, L. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09140-x · Cited by 360
Melin, B. S., Barnholtz-Sloan, J. S., Wrensch, M. R., Johansen, C., Il'yasova, D., Kinnersley, B., Ostrom, Q. T., Labreche, K., Chen, Y., Armstrong, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3823 · Cited by 350
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9990 · Cited by 350
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8726 · Cited by 349
Glioma synapses recruit mechanisms of adaptive plasticity
Taylor, K. R., Barron, T., Hui, A., Spitzer, A., Yalçin, B., Ivec, A. E., Geraghty, A. C., Hartmann, G. G., Arzt, M., Gillespie, S. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06678-1 · Cited by 342
Self-citationvan den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 330
Self-citationOncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
Friedman, G. K., Johnston, J. M., Bag, A. K., Bernstock, J. D., Li, R., Aban, I., Kachurak, K., Nan, L., Kang, K.-D., Totsch, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024947 · Cited by 328
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 324
Self-citationVitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., Künkele, A., Chang, C. A., Rawlings-Rhea, S., Huang, W., Seidel, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01404-8 · Cited by 321
Merchant, T. E., Mulhern, R. K., Krasin, M. J., Kun, L. E., Williams, T., Li, C., Xiong, X., Khan, R. B., Lustig, R. H., Boop, F. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.142 · Cited by 314
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
EANO guidelines for the diagnosis and treatment of ependymal tumors
Rudà, R., Reifenberger, G., Frappaz, D., Pfister, S. M., Laprie, A., Santarius, T., Roth, P., Tonn, J. C., Soffietti, R., Weller, M., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox166 · Cited by 299
Self-citationOncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nassiri, F., Patil, V., Yefet, L. S., Singh, O., Liu, J., Dang, R. M. A., Yamaguchi, T. N., Daras, M., Cloughesy, T. F., Colman, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02347-y · Cited by 293
Reinhardt, A., Stichel, D., Schrimpf, D., Sahm, F., Korshunov, A., Reuss, D. E., Koelsche, C., Huang, K., Wefers, A. K., Hovestadt, V., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1837-8 · Cited by 289
Self-citationWen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J.-J., Glantz, M., Peereboom, D. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0261 · Cited by 287
Self-citationSievert, A. J., & Fisher, M. J. (2009) · Journal of Child Neurology · doi:10.1177/0883073809342005 · Cited by 285
Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz124 · Cited by 278
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Bandopadhayay, P., Ramkissoon, L. A., Jain, P., Bergthold, G., Wala, J., Zeid, R., Schumacher, S. E., Urbanski, L., O'Rourke, R., Gibson, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3500 · Cited by 277
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Ling, A. L., Solomon, I. H., Landivar, A. M., Nakashima, H., Woods, J. K., Santos, A., Masud, N., Fell, G., Mo, X., Yilmaz, A. S., et al. (2023) · Nature · doi:10.1038/s41586-023-06623-2 · Cited by 276
Self-citationAtopy and Risk of Brain Tumors: A Meta-analysis
Linos, E., Raine, T., Alonso, A., & Michaud, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm170 · Cited by 275
Hauptmann, M., Byrnes, G., Cardis, E., Bernier, M.-O., Blettner, M., Dabin, J., Engels, H., Istad, T. S., Johansen, C., Kaijser, M., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00655-6 · Cited by 273 · cited 1×
“…who underwent cranial CT examinations before the age of 22 years reported a significant dose–response relationship between CT-related radiation exposure and brain cancer risk, thus demanding careful justification of paediatric CT and use of radiation doses as low as reasonably possible 12 .”
Clarke, M., Mackay, A., Ismer, B., Pickles, J. C., Tatevossian, R. G., Newman, S., Bale, T. A., Stoler, I., Izquierdo, E., Temelso, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1030 · Cited by 271
Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 271
Self-citationNúñez, F. J., Mendez, F. M., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C., Calinescu, A.-A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 269
Huse, J. T., Snuderl, M., Jones, D. T. W., Brathwaite, C. D., Altman, N., Lavi, E., Saffery, R., Sexton-Oates, A., Blumcke, I., Capper, D., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1639-9 · Cited by 268
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., Hübner, J.-M., Ramaswamy, V., Jia, S., Dalton, J. D., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1877-0 · Cited by 262
Sonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., Gomez, C., Bebawy, J. F., Liu, B. P., Bouchoux, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00112-2 · Cited by 260
Chan, J. A., Zhang, H., Roberts, P. S., Jozwiak, S., Wieslawa, G., Lewin-Kowalik, J., Kotulska, K., & Kwiatkowski, D. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1236 · Cited by 258
Sadetzki, S., Chetrit, A., Freedman, L., Stovall, M., Modan, B., & Novikov, I. (2005) · Radiation Research · doi:10.1667/rr3329 · Cited by 257
Molecular Genetic Analysis of Ependymal Tumors
Ebert, C., von Haken, M., Meyer-Puttlitz, B., Wiestler, O. D., Reifenberger, G., Pietsch, T., & von Deimling, A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65158-9 · Cited by 257
Self-citationAutonomous rhythmic activity in glioma networks drives brain tumour growth
Hausmann, D., Hoffmann, D. C., Venkataramani, V., Jung, E., Horschitz, S., Tetzlaff, S. K., Jabali, A., Hai, L., Kessler, T., Azoŕin, D. D., et al. (2023) · Nature · doi:10.1038/s41586-022-05520-4 · Cited by 254
NF1 mutation drives neuronal activity-dependent initiation of optic glioma
Pan, Y., Hysinger, J. D., Barron, T., Schindler, N. F., Cobb, O., Guo, X., Yalçın, B., Anastasaki, C., Mulinyawe, S. B., Ponnuswami, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03580-6 · Cited by 251
Self-citationPanwalkar, P., Clark, J., Ramaswamy, V., Hawes, D., Yang, F., Dunham, C., Yip, S., Hukin, J., Sun, Y., Schipper, M. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1752-4 · Cited by 248
Ellison, D. W., Hawkins, C., Jones, D. T. W., Onar-Thomas, A., Pfister, S. M., Reifenberger, G., & Louis, D. N. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01987-0 · Cited by 247
Self-citationMiller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 242
Self-citationTurcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective
Mathur, R., Wang, Q., Schupp, P. G., Nikolic, A., Hilz, S., Hong, C., Grishanina, N. R., Kwok, D., Stevers, N. O., Jin, Q., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.013 · Cited by 236
Self-citationGlobal incidence of malignant brain and other central nervous system tumors by histology, 2003–2007
Leece, R., Xu, J., Ostrom, Q. T., Chen, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox091 · Cited by 235
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Lin, G. L., Wilson, K. M., Ceribelli, M., Stanton, B. Z., Woo, P. J., Kreimer, S., Qin, E. Y., Zhang, X., Lennon, J., Nagaraja, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0064 · Cited by 234
Self-citationHorbinski, C., Nabors, L. B., Portnow, J., Baehring, J., Bhatia, A., Bloch, O., Brem, S., Butowski, N., Cannon, D. M., Chao, S., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0002 · Cited by 234
Self-citationPhase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
Bouffet, E., Jakacki, R., Goldman, S., Hargrave, D., Hawkins, C., Shroff, M., Hukin, J., Bartels, U., Foreman, N., Kellie, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5843 · Cited by 233
Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma
Bainbridge, M. N., Armstrong, G. N., Gramatges, M. M., Bertuch, A. A., Jhangiani, S. N., Doddapaneni, H., Lewis, L., Tombrello, J., Tsavachidis, S., Liu, Y., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju384 · Cited by 227
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou059 · Cited by 223
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0764 · Cited by 223
Self-citationBarnholtz-Sloan, J. S., Ostrom, Q. T., & Cote, D. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.001 · Cited by 222
Bell, E. H., Zhang, P., Shaw, E. G., Buckner, J. C., Barger, G. R., Bullard, D. E., Mehta, M. P., Gilbert, M. R., Brown, P. D., Stelzer, K. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02983 · Cited by 219
Ultra-fast deep-learned CNS tumour classification during surgery
Vermeulen, C., Pagès-Gallego, M., Kester, L., Kranendonk, M. E. G., Wesseling, P., Verburg, N., de Witt Hamer, P., Kooi, E. J., Dankmeijer, L., van der Lugt, J., et al. (2023) · Nature · doi:10.1038/s41586-023-06615-2 · Cited by 216 · cited 1×
“Factors that affect health-related quality of life”
Fares, J., Ahmed, A. U., Ulasov, I. V., Sonabend, A. M., Miska, J., Lee-Chang, C., Balyasnikova, I. V., Chandler, J. P., Portnow, J., Tate, M. C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00245-x · Cited by 215
Hargrave, D. R., Bouffet, E., Tabori, U., Broniscer, A., Cohen, K. J., Hansford, J. R., Geoerger, B., Hingorani, P., Dunkel, I. J., Russo, M. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2177 · Cited by 214
An update on the CNS manifestations of neurofibromatosis type 2
Coy, S., Rashid, R., Stemmer-Rachamimov, A., & Santagata, S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02029-5 · Cited by 213
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Krueger, D. A., Care, M. M., Agricola, K., Tudor, C., Mays, M., & Franz, D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e3182815428 · Cited by 210
Happold, C., Gorlia, T., Chinot, O., Gilbert, M. R., Nabors, L. B., Wick, W., Pugh, S. L., Hegi, M., Cloughesy, T., Roth, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6563 · Cited by 210
Self-citationTherapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Mohile, N. A., Messersmith, H., Gatson, N. T., Hottinger, A. F., Lassman, A., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02036 · Cited by 202
Albert, N. L., Galldiks, N., Ellingson, B. M., van den Bent, M. J., Chang, S. M., Cicone, F., de Groot, J., Koh, E., Law, I. G., Rhun, É. L., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00525-9 · Cited by 202
Self-citationChi, A. S., Tarapore, R. S., Hall, M. D., Shonka, N., Gardner, S., Umemura, Y., Sumrall, A., Khatib, Z., Mueller, S., Kline, C., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03271-3 · Cited by 199
Self-citationSame-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
Euskirchen, P., Bielle, F., Labreche, K., Kloosterman, W. P., Rosenberg, S., Daniau, M., Schmitt, C., Masliah-Planchon, J., Bourdeaut, F., Dehais, C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1743-5 · Cited by 196
MYCN amplification drives an aggressive form of spinal ependymoma
Ghasemi, D. R., Sill, M., Okonechnikov, K., Korshunov, A., Yip, S., Schutz, P. W., Scheie, D., Kruse, A., Harter, P. N., Kastelan, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02056-2 · Cited by 188
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis
Chen, C. C. L., Deshmukh, S., Jessa, S., Hadjadj, D., Lisi, V., Andrade, A. F., Faury, D., Jawhar, W., Dali, R., Suzuki, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.012 · Cited by 188
Bouffet, E., Geoerger, B., Moertel, C., Whitlock, J. A., Aerts, I., Hargrave, D., Osterloh, L., Tan, E., Choi, J., Russo, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01000 · Cited by 188
Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review
IJzerman-Korevaar, M., Snijders, T. J., de Graeff, A., Teunissen, S. C. C. M., & de Vos, F. Y. F. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03015-9 · Cited by 187
Hollon, T., Jiang, C., Chowdury, A., Nasir-Moin, M., Kondepudi, A., Aabedi, A., Adapa, A., Al-Holou, W., Heth, J., Sagher, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02252-4 · Cited by 183
Jakacki, R. I., Cohen, K. J., Buxton, A., Krailo, M. D., Burger, P. C., Rosenblum, M. K., Brat, D. J., Hamilton, R. L., Eckel, S. P., Zhou, T., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now038 · Cited by 182
Taylor, A. J., Little, M. P., Winter, D. L., Sugden, E., Ellison, D. W., Stiller, C. A., Stovall, M., Frobisher, C., Lancashire, E. R., Reulen, R. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0090 · Cited by 179
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Doz, F., van Tilburg, C. M., Geoerger, B., Højgaard, M., Øra, I., Boni, V., Capra, M., Chisholm, J., Chung, H. C., DuBois, S. G., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noab274 · Cited by 179
Hervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., Ammanuel, S., Kakaizada, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02929 · Cited by 175
Self-citationEverolimus for subependymal giant cell astrocytoma: 5‐year final analysis
Franz, D. N., Agricola, K., Mays, M., Tudor, C., Care, M. M., Holland‐Bouley, K., Berkowitz, N., Miao, S., Peyrard, S., & Krueger, D. A. (2015) · Annals of Neurology · doi:10.1002/ana.24523 · Cited by 173
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 172
Outcome analysis of childhood low‐grade astrocytomas
Fisher, P. G., Tihan, T., Goldthwaite, P. T., Wharam, M. D., Carson, B. S., Weingart, J. D., Repka, M. X., Cohen, K. J., & Burger, P. C. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21563 · Cited by 170
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Sahm, F., Koelsche, C., Meyer, J., Pusch, S., Lindenberg, K., Mueller, W. C., Herold‐Mende, C. C., von Deimling, A., & Hartmann, C. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0993-5 · Cited by 168
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Ahluwalia, M. S., Reardon, D. A., Abad, A. P., Curry, W. T., Wong, E. T., Figel, S. A., Mechtler, L. L., Peereboom, D. M., Hutson, A. D., Withers, H. G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00996 · Cited by 165
Bahuau, M., Vidaud, D., Jenkins, R. B., Bièche, I., Kimmel, D. W., Assouline, B., Smith, J. S., Alderete, B. E., Cayuela, J., Harpey, J. P., et al. (1998) · PubMed · Cited by 163
Hegi, M. E., Genbrugge, E., Gorlia, T., Stupp, R., Gilbert, M. R., Chinot, O. L., Nabors, B., Jones, G., Criekinge, W. V., Straub, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3181 · Cited by 162
Self-citationWalbert, T., Harrison, R. A., Schiff, D., Avila, E. K., Chen, M., Kandula, P., Lee, J. W., Le Rhun, E., Stevens, G. H. J., Vogelbaum, M. A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab152 · Cited by 162
Self-citationOutcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
Nobre, L. F., Zápotocký, M., Ramaswamy, V., Ryall, S. T., Bennett, J., Alderete, D., Guill, J. B., Baroni, L., Bartels, U. K., Bavle, A. A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00298 · Cited by 158
Bady, P., Delorenzi, M., & Hegi, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.009 · Cited by 157
Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma
Michealraj, K. A., Kumar, S. A., Kim, L. J. Y., Cavalli, F. M. G., Przelicki, D., Wojcik, J. B., Delaidelli, A., Bajic, A., Saulnier, O., MacLeod, G. D. A. H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.047 · Cited by 156
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, D. D., Savani, M. R., Levitt, M. M., Wang, A. C., Endress, J. E., Bird, C. E., Buehler, J., Stopka, S. A., Regan, M. S., Lin, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.011 · Cited by 153
Daniels, T. B., Brown, P. D., Felten, S. J., Wu, W., Buckner, J. C., Arusell, R. M., Curran, W. J., Abrams, R. A., Schiff, D., & Shaw, E. G. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.003 · Cited by 151
Kadiyala, P., Carney, S. V., Gauss, J. C., Garcia-Fabiani, M. B., Haase, S., Alghamri, M. S., Núñez, F. J., Liu, Y., Yu, M., Taher, A. W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139542 · Cited by 151
Hwang, E. I., Jakacki, R. I., Fisher, M. J., Kilburn, L. B., Horn, M., Vézina, G., Rood, B. R., & Packer, R. J. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24297 · Cited by 145
Sievers, P., Sill, M., Schrimpf, D., Stichel, D., Reuß, D., Sturm, D., Hench, J., Frank, S., Krsková, L., Vícha, A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa251 · Cited by 139
Self-citationSahm, F., Brandner, S., Bertero, L., Capper, D., French, P. J., Figarella‐Branger, D., Giangaspero, F., Haberler, C., Hegi, M. E., Kristensen, B. W., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad100 · Cited by 139
Self-citationTAPHOORN, M. J. B., Henriksson, R., Bottomley, A., Cloughesy, T. F., Wick, W., Mason, W. P., Saran, F. H., Nishikawa, R., Hilton, M., Theodore‐Oklota, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3217 · Cited by 137
Heterogeneity within the PF-EPN-B ependymoma subgroup
Cavalli, F. M. G., Hübner, J.-M., Sharma, T. S., Luu, B., Sill, M., Zápotocký, M., Mack, S. C., Witt, H., Lin, T., Shih, D. J. H., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1888-x · Cited by 135
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Self-citationSuh, C. H., Kim, H. S., Jung, S. C., Choi, C. G., & Kim, S. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy113 · Cited by 132
Alexandrescu, S., Korshunov, A., Lai, S. H., Dabiri, S., Patil, S., Li, R., Shih, C., Bonnin, J. M., Baker, J. A., Du, E. Z., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12295 · Cited by 129
Ependymoma: Evaluation and Management Updates
Rudà, R., Bruno, F., Pellerino, A., & Soffietti, R. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01260-w · Cited by 129
Appay, R., Dehais, C., Colin, C., Alentorn, A., Carpentier, C., Ducray, F., Ibdaih, A., Kamoun, A., Mokhtari, K., Tabouret, E., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz126.000 · Cited by 126
Avila, E. K., Tobochnik, S. D., Inati, S. K., Koekkoek, J. A. F., McKhann, G. M., Riviello, J. J., Rudà, R., Schiff, D., Tatum, W. O., Templer, J. W., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad154 · Cited by 125
Self-citationZhou, J., Shrikhande, G., Xu, J., McKay, R. M., Burns, D. K., Johnson, J. E. B., & Parada, L. F. (2011) · Genes & Development · doi:10.1101/gad.16750211 · Cited by 121
Jaeckle, K. A., Ballman, K. V., van den Bent, M., Giannini, C., Galanis, E., Brown, P. D., Jenkins, R. B., Cairncross, J. G., Wick, W., Weller, M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noaa168 · Cited by 119
Self-citationChiocca, E. A., Gelb, A. B., Chen, C. C., Rao, G., Reardon, D. A., Wen, P. Y., Bi, W. L., Peruzzi, P., Amidei, C., Triggs, D., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab271 · Cited by 119
Self-citationPrzystal, J. M., Cosentino, C. C., Yadavilli, S., Zhang, J., Laternser, S., Bonner, E. R., Prasad, R., Dawood, A., Lobeto, N., Chong, W. C., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac041 · Cited by 116
Suwala, A. K., Stichel, D., Schrimpf, D., Kloor, M., Wefers, A. K., Reinhardt, A., Maas, S. L. N., Kratz, C. P., Schweizer, L., Hasselblatt, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02243-6 · Cited by 113
Pajtler, K. W., Wei, Y., Okonechnikov, K., Silva, P. B. G., Vouri, M., Zhang, L., Brabetz, S., Sieber, L., Gulley, M., Mauermann, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11884-5 · Cited by 112
Mondal, G., Lee, J. C., Ravindranathan, A., Villanueva-Meyer, J. E., Tran, Q. T., Allen, S. J., Barreto, J., Gupta, R. K., Doo, P., Ziffle, J. V., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02155-5 · Cited by 110
Lassman, A. B., Hoang‐Xuan, K., Polley, M. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., TAPHOORN, M. J. B., Souhami, L., Dinjens, W. N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02543 · Cited by 104
Zheng, T., Ghasemi, D. R., Okonechnikov, K., Korshunov, A., Sill, M., Maaß, K. K., da Silva, P. B. G., Ryzhova, M. V., Gojo, J., Stichel, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0963 · Cited by 102
Self-citationMortazavi, A., Fayed, I., Bachani, M., Dowdy, T., Jahanipour, J., Khan, A. U., Owotade, J., Walbridge, S., Inati, S. K., Steiner, J. P., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac003 · Cited by 102
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil-Gil, M. J., Puduvalli, V. K., Raizer, J. J., Vos, F. D., Wen, P. Y., Butowski, N. A., Clément, P. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2664 · Cited by 102
Self-citationRoth, P., Pace, A., Rhun, É. L., Weller, M., Ay, C., Moyal, E. C., Coomans, M. B., Giusti, R., Jordan, K., Nishikawa, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.003 · Cited by 101
Self-citationActivated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation
Robinson, J. P., VanBrocklin, M. W., Guilbeault, A. R., Signorelli, D. L., Brandner, S., & Holmen, S. L. (2009) · Oncogene · doi:10.1038/onc.2009.333 · Cited by 99
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Graßl, N., Poschke, I. C., Lindner, K. A. M., Bunse, L., Mildenberger, I. C., Boschert, T., Jähne, K., Green, E. W., Hülsmeyer, I., Jünger, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02555-6 · Cited by 99
Ellingson, B. M., Leu, K., Pope, W. B., Lai, A., Nghiemphu, P. L., Liau, L. M., & Cloughesy, T. F. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov225.24 · Cited by 98
ZFTA–RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma
Arabzade, A., Zhao, Y., Varadharajan, S., Chen, H., Jessa, S., Rivas, B. L., Stuckert, A. J., Solis, M., Kardian, A., Tlais, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1066 · Cited by 95
Cited by
Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
Wang, C., Xue, Y., Markovic, T., Li, H., Wang, S., Zhong, Y., Du, S., Zhang, Y., Hou, X., Yu, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02114-5 · Cited by 171
“GBM represents the most aggressive and lethal form of primary brain tumour 53 .”
A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma
Gao, Y., Mao, M., Li, Y., Xuan, M., Wu, Y., & He, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-60422-z · Cited by 42
Metadata
- Authors
- Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G.
- Venue
- Nature Reviews Disease Primers
- Published
- 2024-05-09
- Volume
- 10
- Issue
- 1
- Pages
- 33-33
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4396762217
- Cited by
- 592
- References
- 264
- FWCI
- 77.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.